Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.93) by $0.26, Zacks reports.
Aptevo Therapeutics Trading Down 10.6 %
NASDAQ APVO traded down $0.04 during mid-day trading on Friday, hitting $0.37. The company’s stock had a trading volume of 134,978 shares, compared to its average volume of 2,782,679. The stock’s fifty day simple moving average is $0.49 and its two-hundred day simple moving average is $2.62. Aptevo Therapeutics has a 52-week low of $0.28 and a 52-week high of $22.93.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on shares of Aptevo Therapeutics in a research note on Saturday. They issued a “sell” rating on the stock.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Featured Stories
- Five stocks we like better than Aptevo Therapeutics
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- What Are Dividend Challengers?
- MarketBeat Week in Review – 8/5 – 8/9
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
